Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Is computer-assisted aminoglycoside dosing managed by a pharmacist a safety tool of pharmacotherapy

E. Dvořáčková, P. Pávek, B. Kováčová, J. Rychlíčková, O. Suchopár, M. Hojný, J. D. Tebbens, J. Vlček

. 2019 ; 68 (Suppl 1) : S87-S96. [pub] 20191122
. 2019 ; () : S87-S96.

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21028159

This pilot prospective study verified the hypothesis that use of computer-assisted therapeutic drug monitoring of aminoglycosides by pharmacists leads to better safety therapeutic outcomes and cost avoidance than only concentration measurement and dose adjustments based on a physician's experience. Two groups of patients were enrolled according to the technique of monitoring. Patients (Group 1, n=52) underwent monitoring by a pharmacist using pharmacokinetic software. In a control group (Group 2, n=11), plasma levels were measured but not interpreted by the pharmacist, only by physicians. No statistically significant differences were found between the groups in factors influenced by therapy. However, the results are not statistically significant but a comparison of the groups showed a clear trend towards safety and cost avoidance, thus supporting therapeutic drug monitoring. Safety limits were achieved in 76 % and 63 % of cases in Groups 1 and 2, respectively. More patients achieved both concentrations (peak and trough) with falling eGFR in Group 1. In present pilot study, the pharmacist improved the care of patients on aminoglycoside therapy. A larger study is needed to demonstrate statistically significantly improved safety and cost avoidance of aminoglycoside therapy monitoring by the pharmacist using pharmacokinetic software.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21028159
003      
CZ-PrNML
005      
20220328133808.0
007      
ta
008      
211105s2019 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934329 $2 doi
035    __
$a (PubMed)31755294
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Dvořáčková, Eliška $7 kv2015890922 $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Hradec Králové, Czech Republic $u Hospital Pharmacy, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Is computer-assisted aminoglycoside dosing managed by a pharmacist a safety tool of pharmacotherapy / $c E. Dvořáčková, P. Pávek, B. Kováčová, J. Rychlíčková, O. Suchopár, M. Hojný, J. D. Tebbens, J. Vlček
504    __
$a Literatura
520    9_
$a This pilot prospective study verified the hypothesis that use of computer-assisted therapeutic drug monitoring of aminoglycosides by pharmacists leads to better safety therapeutic outcomes and cost avoidance than only concentration measurement and dose adjustments based on a physician's experience. Two groups of patients were enrolled according to the technique of monitoring. Patients (Group 1, n=52) underwent monitoring by a pharmacist using pharmacokinetic software. In a control group (Group 2, n=11), plasma levels were measured but not interpreted by the pharmacist, only by physicians. No statistically significant differences were found between the groups in factors influenced by therapy. However, the results are not statistically significant but a comparison of the groups showed a clear trend towards safety and cost avoidance, thus supporting therapeutic drug monitoring. Safety limits were achieved in 76 % and 63 % of cases in Groups 1 and 2, respectively. More patients achieved both concentrations (peak and trough) with falling eGFR in Group 1. In present pilot study, the pharmacist improved the care of patients on aminoglycoside therapy. A larger study is needed to demonstrate statistically significantly improved safety and cost avoidance of aminoglycoside therapy monitoring by the pharmacist using pharmacokinetic software.
650    _2
$a senioři $7 D000368
650    _2
$a amikacin $x aplikace a dávkování $7 D000583
650    _2
$a aminoglykosidy $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000617
650    _2
$a antibakteriální látky $x aplikace a dávkování $7 D000900
650    _2
$a náklady a analýza nákladů $7 D003365
650    12
$a výpočet dávky léku $7 D054796
650    _2
$a monitorování léčiv $x ekonomika $x metody $7 D016903
650    _2
$a počítačová farmakoterapie $x metody $7 D004360
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gentamiciny $x aplikace a dávkování $7 D005839
650    _2
$a lidé $7 D006801
650    _2
$a nemoci ledvin $x chemicky indukované $7 D007674
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a farmaceuti $7 D010595
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a bezpečnost $7 D012449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pávek, Petr $7 xx0093070 $u Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Králové, Czech Republic
700    1_
$a Kováčová, Barbora $7 xx0244558 $u Department of Clinical Pharmacy, Teaching Hospital, Plzeň, Czech Republic
700    1_
$a Rychlíčková, Jitka $7 xx0230558 $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Clinical Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Suchopár, Ondřej $7 xx0267295 $u Drugagency a.s., Prague, Czech Republic
700    1_
$a Hojný, Michal, $d 1976- $7 xx0104476 $u Hospital Pharmacy, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Tebbens, Jurjen Duintjer $7 _AN084306 $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic
700    1_
$a Vlček, Jiří, $d 1954- $7 jn20000402562 $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, Suppl 1 (2019), s. S87-S96
773    0_
$t 69th Czech-Slovak pharmacological days $g (2019), s. S87-S96 $w MED00208902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31755294 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20211105 $b ABA008
991    __
$a 20220328133806 $b ABA008
999    __
$a ok $b bmc $g 1728762 $s 1148704
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 68 $c Suppl 1 $d S87-S96 $e 20191122 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
BMC    __
$a 2019 $d S87-S96 $m 69th Czech-Slovak pharmacological days $x MED00208902
LZP    __
$b NLK118 $a Pubmed-20211105

Find record

Citation metrics

Archiving options